[The story about Hodgkin's lymphoma].
The exciting story about Hodgkin's lymphoma is 170 years old. Today, we know a lot about biology of this B cell neoplasma (derived from the germinative center), and the diagnostic standard criteria are clearly defined and accepted. Although the definition of prognostic factors for early disease varies between different study groups as well as the definition of advanced disease therapeutic aim is same for all clinicans: preserving the high cure rates while reducing the acute and long-term toxicities. Today, with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy followed by radiotherapy in some patients' group, more than 85% patients can be cured. Maybe, the recently published results of the latest researches in Hodgkin's lymphoma (evidence for the cancer stem cell; the role of T cells in tumour microenvironment in survival of lymphomas cells; the role of galectin-1 in tumor escape in Hodgkin's lymphoma) will help us to reach our therapeutic goal: cure for all patients with Hodgkin's lymphoma!